The short answer

GLP-1 telehealth means getting evaluated and prescribed semaglutide or tirzepatide by a licensed provider over video or asynchronous intake, rather than in person — the medication itself is the same FDA-approved product (or, in narrow cases, a patient-specific compounded version) you’d get from a brick-and-mortar clinic. It’s legal in all 50 states. The parts that vary a lot between platforms are how thorough the intake is, whether ongoing monitoring is built in, and whether you’re getting a brand-name product or a compounded one.

What the process actually looks like

1. Intake. You complete a medical history form covering weight, height, BMI, relevant conditions (thyroid history, pancreatitis, family history of certain cancers), and current medications. Rigorous platforms also ask about cardiometabolic risk factors, not just weight.
2. Clinician review. A licensed physician, nurse practitioner, or physician assistant reviews your intake — sometimes with a live video visit, sometimes asynchronously — and decides whether a GLP-1 is appropriate, and which one.
3. Prescription and fulfillment. If approved, the prescription routes to a pharmacy. For an FDA-approved brand (Wegovy, Zepbound, Ozempic, Mounjaro), that’s typically a standard retail or mail-order pharmacy. For a compounded version, it must be a patient-specific prescription filled by a 503A pharmacy — mass-produced compounded semaglutide is no longer a legal offering as of 2026 (see compounded vs brand-name semaglutide).
4. Delivery and titration. Medication ships to you, typically with a dosing schedule that starts low and increases over weeks to reduce GI side effects.
5. Follow-up. Reputable programs schedule check-ins — often monthly — to track side effects, weight trend, and whether to adjust dose. This is also where a provider would catch things like excessive weight loss or intolerable side effects.

What actually varies between platforms

• Depth of intake. Some platforms request bloodwork or ask for it if you have risk factors; others approve based on self-reported history alone. A thin intake isn’t automatically disqualifying, but it’s worth knowing what you’re getting.
• Brand vs. compounded. Several major platforms shifted toward brand-name-first models in 2026, offering compounded formulations only when a clinician documents a specific reason (see the compounded-vs-brand explainer linked above). If a platform is still advertising standard compounded semaglutide with no clinical justification requested, that’s a compliance red flag, not a convenience.
• Ongoing support. Some programs bundle structured check-ins, symptom tracking, and dose-adjustment protocols; others are closer to a one-time consult plus refills. If you want more support around side effects and plateaus, ask what the follow-up cadence actually is before signing up.

Red flags to watch for

• No licensed clinician is named or reachable, or “approval” happens with no medical questions asked.
• Compounded semaglutide or tirzepatide offered without any request for a patient-specific clinical reason.
• Guaranteed approval, or marketing language that promises a specific amount of weight loss.
• No mechanism to report side effects or reach a provider between refills.

The next step

If you’re considering GLP-1 telehealth, the practical next step is comparing a couple of licensed platforms on the specifics that matter to you — intake depth, brand vs. compounded, and follow-up structure — and asking direct questions before enrolling. For what this actually costs across brand, cash-pay, and telehealth-bundled paths, see how much GLP-1s cost via telehealth in 2026, and check the legal status tracker for where compounding stands today.

Sources

• FDA — Section 503A compounding requirements
• FDA — “FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize”
• STAT News — coverage of telehealth GLP-1 prescribing practices

Educational content only — not medical advice, and not a recommendation to use any specific medication or platform. Always consult a licensed healthcare professional.

← All articles